“…They develop in both immunocompromised hosts and in patients with DM, malignancy, hepatobiliary disease and haematological disease. Interestingly, it also develops in conditions associated with iron overload, status such as in patients demonstrating sickle cell disease, cirrhosis, leukemia and in neonates (2,3). Almost all E. tarda strains are susceptible to antibiotics with an activity against Gramnegative bacilli, including most beta-lactams, aminoglycosides, tetracyclines, fluoroquinolones and antifolates (12).…”